Marksans Pharma Ltd

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for its product Exemestane 25mg film-coated tablets from UK MHRA.Powered by Capital Market - Live

Marksans Pharma announced that CFC Finlease, a SEBI Licensed ESG Rating Provider (ERP), has voluntarily reviewed the ESG rating on the Company, based on data available in public domain for the Fiscal 2025, and assigned an ESG Score of '73'.Powered by Capital Market - Live

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for the below-mentioned products from UK MHRA: Clonidine 100 microgram Tablets Clonidine Hydrochloride 25 microgram TabletsPowered by Capital Market - Live

Marksans Pharma has received upgrade in long term bank facilities of Rs 135 crore at CARE AA-; Stable (upgraded from CARE A+; Positive). The rating on short term bank facilities of Rs 120.75 crore is affirmed at CARE A1+. Powered by Capital Market - Live

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for the below-mentioned products from UK MHRA: 1. Moxonidine 200 microgram Tablets 2. Moxonidine 400 microgram TabletsPowered by Capital Market - Live

The approval was granted by the UK regulatory authorities, allowing Relonchem to market the widely used anti-diabetic medication in three dosage strengths. Metformin is commonly prescribed for the treatment of type 2 diabetes and is considered a frontline therapy for managing blood glucose levels. Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The company's consolidated net profit dropped 34.3% to Rs 58.31 crore despite of 4.97% jump in revenue from operations to Rs 619.98 crore in Q1 FY26 over Q1 FY25. Powered by Capital Market - Live

Marksans Pharma  announced that its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for the below-mentioned products from UK MHRA: Metformin Hydrochloride Relonchem 500 mg Prolonged Release Tablets Metformin Hydrochloride Relonchem 750 mg Prolonged Release Tablets Metformin Hydrochloride Relonchem 1000 mg Prolonged Release TabletsPowered by Capital Market - Live

Net profit of Marksans Pharma declined 34.29% to Rs 58.32 crore in the quarter ended June 2025 as against Rs 88.75 crore during the previous quarter ended June 2024. Sales rose 4.97% to Rs 619.99 crore in the quarter ended June 2025 as against Rs 590.62 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales619.99590.62 5 OPM %16.1521.75 - PBDT99.70140.46 -29 PBT76.60120.02 -36 NP58.3288.75 -34 Powered by Capital Market - Live

The growth in revenue from operations was fueled by the US market, with contributions from new product launches in the gastrointestinal, pain management, and digestive health segments Profit before tax (PBT) declined 36.18% YoY to Rs 76.59 crore during the quarter. EBITDA slipped 22% to Rs 100.1 crore in Q1 June 2025, compared with Rs 128.4 crore posted in Q1 June 2024. EBITDA margin fell 560 bps to 16.1% in Q1 FY26 as against 21.7% in Q1 FY25. During the quarter, revenue from US & North America stood at Rs 327.6 crore (up 30.6% YoY) while revenue from UK and Europe stood at Rs 203.8 crore (down 19% YoY). Revenue from Australia and New Zealand business stood at Rs 57 crore (down 13.1% YoY) in Q1 FY26. Rest of World (ROW) business grew by 39.4% YoY to Rs 31.6 crore during the period under review. As of 30th June 2025, cash balance stood at Rs 711 crore. Research & Development (R&D) for Q1FY26 was Rs 12.1 crore, 2.0% of consolidated revenue. Mark Saldanha, managing director, Marksans Pharma, said, 'While Q1FY26 was a seasonally soft quarter, we delivered year-on-year revenue growth of 5%, while gross profit increased by 8.9%. This was supported by successful new product launches in the US markets and the easing of raw material costs. While EBITDA and net profit margins were impacted by ramp-up costs, a one-time ECL provision for the emerging market division, and forex adjustments, these are transient and do not affect the fundamental momentum of our business. We are already seeing encouraging early signs of demand recovery in key markets such as the U.S., U.K., and Australia. With the Goa facility integration nearing completion, we are now sharply focused on scaling capacity, enhancing operational efficiency, and unlocking synergies.' Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.Powered by Capital Market - Live